We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DPH Dechra Pharmaceuticals Plc

4.00 (0.1%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  4.00 0.1% 3,828.00 1,625,664 16:28:29
Bid Price Offer Price High Price Low Price Open Price
3,826.00 3,828.00 3,830.00 3,816.00 3,828.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 761.5M -27.9M -0.2450 -156.24 4.36B
Last Trade Time Trade Type Trade Size Trade Price Currency
17:46:10 O 17,471 3,827.561 GBX

Dechra Pharmaceuticals (DPH) Latest News (17)

Smart Money!
DPH is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 

Dechra Pharmaceuticals (DPH) Discussions and Chat

Dechra Pharmaceuticals Forums and Chat

Date Time Title Posts
07/9/202307:39Dechra Pharmaceuticals Plc629
10/3/201216:10Dechra with Charts9
10/3/201216:10Dechra Pharmaceuticals PLC1

Add a New Thread

Dechra Pharmaceuticals (DPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-01 17:27:403,825.9117,786680,476.71O
2023-12-01 17:27:403,825.9175,0002,869,434.00O
2023-12-01 17:27:053,826.3028410,866.68O
2023-12-01 17:15:003,827.0025,000956,750.00O
2023-12-01 17:15:003,824.0056,4152,157,309.60O

Dechra Pharmaceuticals (DPH) Top Chat Posts

Top Posts
Posted at 02/12/2023 08:20 by Dechra Pharmaceuticals Daily Update
Dechra Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker DPH. The last closing price for Dechra Pharmaceuticals was 3,824p.
Dechra Pharmaceuticals currently has 113,888,190 shares in issue. The market capitalisation of Dechra Pharmaceuticals is £4,359,639,913.
Dechra Pharmaceuticals has a price to earnings ratio (PE ratio) of -156.24.
This morning DPH shares opened at 3,828p
Posted at 05/6/2023 19:27 by robertball
I guess the price will hover until we get a CMA announcement.Any idea as to when?
Posted at 02/6/2023 21:26 by robertball
The return is high because the competition authorities might look into the EQT/ Dechra deal.EQT own IVC Evidensia. This is the Luxembourg company which owns Independent Vetcare Limited.They in turn, have a sizeable share of the UK vet and vet hospital market.Also see tomorrow's Lex in the FT
Posted at 02/6/2023 13:56 by vworlds_cambridge
The price is not good for me, but we are where we are. Had bought this for the long-term. Thanks for all the useful info on here.
Posted at 02/6/2023 06:25 by 1jat
Unlikely another bidder will emerge to raise the price so we will never know what the share price would have been……but it is quite likely that EQT will sell it in 5/10 years and will want double the current offer….
Posted at 01/6/2023 08:58 by steeplejack
Yes i tend to agree.It reads as if tomorrow might well be the 'put up or shut up' deadline.The Company remains in discussion with EQT X EUR SCSp and EQT X USD SCSp, each represented by its manager (gérant) EQT Fund Management S.à r.l. (collectively referred to as "EQT") regarding a possible all-cash recommended offer of 4,070 pence per ordinary share. As announced on 11 May 2023, in accordance with Rule 2.6(a) of the City Code on Takeovers and Mergers (the "Code"), EQT is required, by not later than 5.00 pm (London time) on 2 June 2023 either to announce a firm intention to make an offer for Dechra in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer.
Posted at 30/5/2023 08:44 by lindowcross
Steeple, I agree with your comments at 602 and I'm betting the takeover will proceed at the current mentioned price or close to it. So I bought a few more last week.
Posted at 22/5/2023 15:32 by steeplejack
Yes,the management won’t be that keen if EQT try to bid them down due to destocking which could well prove to be but a temporary interruption to growth.Thereagain,Covid might come to be regarded as something of a ‘temporaryR17; one off benefit to profitability.Unless due diligence throws up something unexpected,my hunch is that EQT might follow through with its originally suggested £40-70p offer.It doesn’t have to answer to shareholders and EQT might well wish to have Ian Page’s unequivocal approval for the bid.The price has an all time high of around £55.Its a pure guess of course and the market seems to be leaning towards EQT walking away.
Posted at 22/5/2023 07:13 by steeplejack
So will EQT adjust its offer to reflect the tough trading conditions currently being encountered.The current price sits near halfway between the price before the bid emerged ie around £26 and the value of the cash bid of a tad over £40.I presume we'll know whether a bid will emerge by June 2,you can't keep kicking the can down the road.
Posted at 10/5/2023 08:31 by phillis
Am not up to date with the rules
DPH could agree to an extension I think
Posted at 05/9/2022 14:04 by km18
Dechra Pharmaceuticals Plc posted Prelims for the FY ended 30th June 2022. Revenues grew 13.8% to £681.8 million, reported operating profit rose 16.2% to £95.5m, underlying diluted EPS increased 14.0% to 120.84 pence and the FY dividend increased by 10.8% to 44.89 pence, all at constant exchange rate. The business has been growing solidly for many years now, but valuation remains unhelpful with forward PE ratio at 27.9x and PS ratio at 6.21x. Share price has been in a correction for most of 2022 and this correction has extended another 10%+ following today’s release. DPH is a high quality and solid growth business, but it is expensive and a share to monitor for now...

...from WealthOracle
Dechra Pharmaceuticals share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |